ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

NDRM Neuroderm Ltd. - Ordinary Shares

38.85
0.00 (0.00%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Neuroderm Ltd. - Ordinary Shares NASDAQ:NDRM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 38.85 38.75 199,999.95 0 01:00:00

Report of Foreign Issuer (6-k)

03/08/2017 10:01pm

Edgar (US Regulatory)


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

______________________

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16 of the

 

Securities Exchange Act of 1934

 

For the month of August 2017

 

Commission File Number: 001-36737

 

NeuroDerm Ltd.

 

(Translation of registrant’s name into English)

 

NeuroDerm Ltd.

Ruhrberg Science Building

3 Pekeris St.

Rehovot 7670212, Israel

+972 (8) 946-2729l

 (Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x    Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   ¨

 

 

 

 

 

 

EXPLANATORY NOTE

 

On August 3, 2017, NeuroDerm Ltd. issued a press release, titled “NeuroDerm Announces Second Quarter 2017 Financial Results.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

 

The information in this Form 6-K (including in Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

  NeuroDerm Ltd.
     
Date: August 3, 2017 By: /s/ Roy Golan
   

Name: Roy Golan

Title: Chief Financial Officer

 

 

 

 

 

 

Exhibit Index

 

Exhibit

  Description
99.1   Press release dated August 3, 2017, titled “NeuroDerm Announces Second Quarter 2017 Financial Results.”
     

 

 

 

 

 

 

 

1 Year NEURODERM LTD. Chart

1 Year NEURODERM LTD. Chart

1 Month NEURODERM LTD. Chart

1 Month NEURODERM LTD. Chart

Your Recent History

Delayed Upgrade Clock